Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,418.00
-22.00 (-1.53%)
At close: Oct 29, 2025
-1.53%
Market Cap133.84B
Revenue (ttm)12.77B
Net Income (ttm)-8.28B
Shares Out94.05M
EPS (ttm)-152.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume206,309
Average Volume326,495
Open1,466.00
Previous Close1,440.00
Day's Range1,418.00 - 1,466.00
52-Week Range1,080.00 - 2,935.00
Beta0.73
RSI47.10
Earnings Daten/a

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.

Financial Statements

News

There is no news available yet.